Program
Letrozole
Also written as “letrozole”, “Letrozole Tablets 2.5 mg” and “Arm C: Gedatolisib + Palbociclib + Letrozole”.
Its studies are mostly in Breast Neoplasms · Neoplasms · Polycystic Ovary Syndrome · Endometrial Neoplasms · Infertility, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 280 open or running | phase 4since Apr 10, 2001 | Apr 10, 2001 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Jun 13, 2011 | Jun 13, 2011 | none ahead |
| Egymedicalpedia | 21 open or running | phase 1since Apr 9, 2024 | Apr 9, 2024 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | phase 1since Jun 3, 2011 | Jun 3, 2011 | none ahead |
| Viatris | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| rovi-pharmaceuticals-laboratories | 10 open or running | phase 1since Jan 8, 2018 | Jan 8, 2018 | none ahead |
| Sun Pharmaceutical Industries | 10 open or running | phase 3since Jan 24, 2008 | Jan 24, 2008 | none ahead |
Also a collaborator on its studies: Gilead Sciences, Pfizer and Hoffmann-La Roche.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Apr 10, 2001.
- Jun 1, 2006Phase 2 study in RecurrenceNovartis · NCT00333086 · 36 enrolled · Germany
- Sep 24, 2007Phase 3 study in Breast NeoplasmsNovartis · NCT00535418 · 35 enrolled
- Jan 24, 2008Sun Pharmaceutical Industries's first study: phase 3 study in InfertilityNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT00610077 · 55 enrolled · India
- Mar 30, 2008Viatris's first studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT00648154, NCT00648063
- May 29, 2008Phase 4 study in Breast NeoplasmsNovartis · NCT00688909 · 261 enrolled · United States
- Oct 28, 2010Phase 2 study in Breast NeoplasmsNovartis · NCT01231659 · 72 enrolled · Israel
- Jun 3, 2011Hikma Pharmaceuticals's first studies: 2 phase 1 studies in Breast NeoplasmsNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT01367652, NCT01367626
- Jun 13, 2011Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01372982, NCT01375452
- Oct 1, 2012Phase 2 study in Breast NeoplasmsNovartis · NCT01698918 · 202 enrolled · United States, Argentina, Brazil and more
- Feb 15, 2017Phase 2 study in Breast NeoplasmsNovartis · NCT03056755 · 383 enrolled · United States, Argentina, Belgium and more
- Jan 8, 2018rovi-pharmaceuticals-laboratories's first study: phase 1 study in HealthyNew to rovi-pharmaceuticals-laboratoriesrovi-pharmaceuticals-laboratories · NCT03401320 · 53 enrolled · Czechia
- Jan 29, 2018Phase 3 study in Breast NeoplasmsNovartis · NCT03439046 · 287 enrolled · Italy
- Apr 9, 2024Egymedicalpedia's first study: phase 1 study in Polycystic Ovary SyndromeNew to EgymedicalpediaEgymedicalpedia · NCT06367712 · 132 enrolled · Egypt
- Jul 7, 2024No phase study in Polycystic Ovary SyndromeEgymedicalpedia · NCT06507332 · 64 planned · Egypt
TargetBeta
“Cytochrome P450 19A1 inhibitor”ChEMBL 37, by rule
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06507332Polycystic Ovary Syndrome · Egypt | – | Recruiting | Egymedicalpedia | Sep 1, 2024 | 64 |
| NCT06367712Polycystic Ovary Syndrome · Egypt | 1 | Completed | Egymedicalpedia | Nov 1, 2023 | 132 |
| NCT03439046Breast Neoplasms · Italy | 3 | Terminated | Novartis | Dec 11, 2023 | 287 |
| NCT03401320Healthy · Czechia | 1 | Completed | rovi-pharmaceuticals-laboratories | May 17, 2024 | 53 |
| NCT03056755Breast Neoplasms · United States, Argentina, Belgium and more | 2 | Completed | Novartis | Jun 14, 2021 | 383 |
| NCT01698918Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Completed | Novartis | Dec 17, 2015 | 202 |
| NCT01375452Healthy | 1 | Completed | Dr. Reddy's Laboratories | May 2008 | 36 |
| NCT01372982Healthy | 1 | Completed | Dr. Reddy's Laboratories | Jun 2008 | 36 |
| NCT01367652Breast Neoplasms · United States | 1 | Completed | Hikma Pharmaceuticals | Apr 2008 | 28 |
| NCT01367626Breast Neoplasms · United States | 1 | Completed | Hikma Pharmaceuticals | Apr 2008 | 28 |
| NCT01231659Breast Neoplasms · Israel | 2 | Completed | Novartis | Nov 20, 2012 | 72 |
| NCT00688909Breast Neoplasms · United States | 4 | Completed | Novartis | Jun 2009 | 261 |
| NCT00648154Healthy · United States | 1 | Completed | Viatris | Dec 2005 | 24 |
| NCT00648063Healthy · United States | 1 | Completed | Viatris | Dec 2005 | 24 |
| NCT00610077Infertility · India | 3 | Completed | Sun Pharmaceutical Industries | Jul 2006 | 55 |
| NCT00535418Breast Neoplasms | 3 | Completed | Novartis | Jul 2002 | 35 |
| NCT00333086Recurrence · Germany | 2 | Completed | Novartis | Jun 2006 | 36 |
| NCT00333047Breast Neoplasms · Germany | 3 | Completed | Novartis | 24 | |
| NCT00332852Breast Neoplasms · Germany | 3 | Completed | Novartis | Jul 2010 | 655 |
| NCT00332709Osteoporosis · Germany | 3 | Completed | Novartis | Aug 2010 | 83 |
| NCT00330317Breast Neoplasms · United Kingdom | 3 | Completed | Novartis | Mar 2010 | 300 |
| NCT00329940Breast Neoplasms · France | 3 | Completed | Novartis | Jan 2008 | 200 |
| NCT00248170Breast Neoplasms · United States, Australia, Austria and more | 3 | Completed | Novartis | Sep 2014 | 4,172 |
| NCT00247663Breast Neoplasms · Japan | 2 | Completed | Novartis | Dec 2005 | 17 |
| NCT00247650Breast Neoplasms · Canada | 2 | Completed | Novartis | Mar 2007 | 190 |
| NCT00241046Breast Neoplasms | 4 | Terminated | Novartis | Mar 2005 | 13 |
| NCT00240942Endometriosis | 2 | Completed | Novartis | Jun 2006 | 40 |
| NCT00237224Breast Neoplasms · Mexico | 4 | Completed | Novartis | Feb 2007 | 40 |
| NCT00237211Breast Neoplasms · Japan | 2 | Completed | Novartis | Oct 2006 | 31 |
| NCT00237198Breast Neoplasms · Japan | 2 | Completed | Novartis | Jul 2006 | 47 |
| NCT00237133Breast Neoplasms · Brazil | 4 | Completed | Novartis | Jan 2009 | 112 |
| NCT00171847Breast Neoplasms · Germany | 4 | Terminated | Novartis | Oct 2008 | 93 |
| NCT00171808Endometrial Neoplasms · Germany | 2 | Completed | Novartis | May 2010 | 26 |
| NCT00171704Breast Neoplasms · Denmark, United Kingdom | 3 | Completed | Novartis | Mar 2011 | 263 |
| NCT00171340Bone Diseases, Metabolic · Argentina, Australia, Belgium and more | 3 | Completed | Novartis | Feb 2010 | 1,065 |
| NCT00171314Breast Neoplasms · Argentina, Belgium, France and more | 3 | Completed | Novartis | Nov 2010 | 527 |
| NCT00050011Breast Neoplasms · United States, Puerto Rico | 3 | Completed | Novartis | Jan 2009 | 602 |
| NCT00014638Breast Neoplasms · United States | 4 | Completed | Novartis | Mar 2002 |
How it is read
Names in the registry
- “Letrozole”, 40 entries
- “letrozole”, 6 entries
- “Letrozole Tablets 2.5 mg”, 2 entries
- “Arm C: Gedatolisib + Palbociclib + Letrozole”, 1 entry
- “PF-07104091 + PF-07220060 + letrozole dose expansion”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 37 studies
- Neoplasms, 2 studies
- Polycystic Ovary Syndrome, 2 studies
- Endometrial Neoplasms, 2 studies
- Infertility, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.